The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback